Granisetron: is there a dose-response effect on nausea and vomiting?

Author: MinamiMasaru

Paper Details 
Original Abstract of the Article :
Nausea and vomiting are two of the most debilitating side effects of cytotoxic chemotherapy. Prevention of nausea and vomiting is, thus, very important to ensure that cancer patients continue to receive optimal cytotoxic therapy while seeking to maintain their quality of life. Significant advances i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s00280-003-0652-6

データ提供:米国国立医学図書館(NLM)

A Quest for a Dose-Response Effect of Granisetron

Nausea and vomiting are unwelcome companions for cancer patients undergoing chemotherapy. The quest for effective antiemetics has been a long one, and the advent of 5-HT(3) receptor antagonists has ushered in a new era of hope. This study focuses on granisetron, a potent antiemetic, and its potential dose-response effect in preventing chemotherapy-induced nausea and vomiting. This is a critical research area as it aims to optimize the effectiveness of antiemetic therapy and improve the quality of life for cancer patients.

Dose-Response Relationship of Granisetron

The researchers investigated the hypothesis that a dose-response relationship exists for granisetron's effectiveness in preventing chemotherapy-induced nausea and vomiting. This is a crucial question as it could pave the way for tailored treatment strategies based on individual patient needs. While the study's findings and specific conclusions aren't included in the abstract, it highlights the importance of understanding this relationship.

Improving Quality of Life for Cancer Patients

This research could lead to more personalized and effective antiemetic strategies for cancer patients. By understanding the dose-response relationship of granisetron, clinicians can potentially optimize treatment plans, minimizing the debilitating side effects of chemotherapy and improving the overall well-being of patients. Imagine this research as a caravan traversing the vast desert of cancer treatment, seeking a safe and effective path for patients.

Dr.Camel's Conclusion

Like a traveler seeking a hidden oasis in the desert, researchers are searching for the optimal dose of granisetron to combat the nausea and vomiting of chemotherapy. This journey of discovery aims to make the desert of cancer treatment less harsh for patients, allowing them to focus on healing instead of discomfort.

Date :
  1. Date Completed 2003-09-30
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

12783208

DOI: Digital Object Identifier

10.1007/s00280-003-0652-6

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.